NFKB1 and myocarditis: GL was capable of treating coxsackievirus B3- (CVB3-) triggered myocarditis via the blockade of CVB3-triggered NF-κB activity via the inhibition of NF-κB inhibitor IκB (Table 1) [20, 64].